

EACR President Anne-Lise Børresen-Dale

President, Anne-Lise Børresen-Dale, looks forward to the EACR-21 conference and reviews some of the changes and developments in the Association over the past twelve months



Anne-Lise Børresen-Dale,

EACR-21

As I look forward to EACR-21 in Oslo in June, I am very aware of how important the meeting is to so many members of the Association. Our recent survey rated the conference as the most highly valued feature of the Association. Members were also pleased with the efforts made to support participation through discounted registration rates and bursaries. By now, I know that most of you will have considered participating in EACR-21 and cannot have failed to be impressed by the quality of the scientific programme. I am thrilled that we have received close to 800 abstracts for evaluation. The size of the meeting will provide wonderful opportunities for members to meet and interact. Please help us to ensure that colleagues who are not yet members of EACR are aware of the conference – perhaps lend them this copy of the Year Book where the programme can be easily reviewed on pages 31 - 35.

New Societies Join EACR

The Association has continued to move forward most successfully over the past two years and there have been some very exciting developments. EACR has been strengthened and enhanced by the affiliation of five more National Societies as EACR members. National societies for cancer research in Belgium, Croatia, Ireland, Israel and Turkey have joined the long standing British, French, German, Hungarian, Italian and Spanish associations in supportive partnership with EACR.

The EACR Symposia Series Develops

Over the past twelve months I have had the opportunity to visit a number of EACR sponsored meetings across Europe, and to join two of the four EACR symposia. These smaller focussed meetings were very successful. In addition to high quality programmes, the meetings provided opportunities for oral presentations selected from abstracts and for poster discussion. There was an encouraging mix of participants at all stages of their careers and feedback was very helpful and most encouraging. A new meetings policy will now support the development of the symposia in response to the high approval rating for such a programme from members.

More Awards and Support for Members

The quality of travel fellowship applications has continued to impress and the increase in funding for this scheme has seen all excellent applications supported. There has been early interest in the match funded fellowships, with two such awards already made.

EACR provides up to 4,000 EUR in partnership with another sponsor providing a matching sum, and this enables a 'longer stay' fellowship to take place. As the match funded award has moved close to the aims of the Mike Price Fellowship, we have decided to introduce a new Mike Price Award which will continue to commemorate the outstanding contribution that Mike made to EACR and FECS (now ECCO). This exciting new award will be outlined shortly on our website.

The Association has also doubled the availability of funds for Meeting Bursaries to attend EACR-21 and we expect to support the participation of more than forty students and early career researchers. We also aim to make a similar number of meeting bursaries available for the ECCO16-36 ESMO meeting next September in Stockholm. This is the first time that EACR has made bursaries available for the ECCO-ESMO meeting and details will be published for members early next year. The ECCO-ESMO meeting in Berlin was well attended by members attracted by stronger programme tracks of interest to them. I am sure that the overall relevance of this multi-disciplinary meeting to members will continue to grow and I look forward to my role in developing the programme as a scientific Co - chair of the ECCO16-36 ESMO meeting.


EACR's Wider Commitment

EACR continues in its role as a founder member of ECCO and the development of this new organisation is impressive, advancing the case for the fight against cancer with a clear and united voice. Our involvement in the Eurocancercoms project is also

very important and I hope that many of you will be able to find time to support the work we are undertaking by taking part in the surveys of opinion, discussion opportunities and even an early morning consensus meeting at EACR-21.

It continues to be a great honour to be president of your Association and I will take pride and pleasure in welcoming so many of you to my home city of Oslo in June for what promises to be an outstanding meeting. After the meeting I will continue my support of EACR as past-president and would like to take this opportunity to wish my successor, Julio Celis, every success during his presidency.

Discovery based translational cancer research







For the full Scientific Programme turn to page 31
Click through for other information, updates and registration from the Meetings page at www.eacr.org

EACR 21

21st Meeting of the EUROPEAN ASSOCIATION FOR CANCER RESEARCH
Oslo | Norway | 26 - 29 June 2010 |

"Join us in Oslo at this most exciting conference on discovery based translational research, discussing the latest breakthroughs in research and how to speed them effectively into the clinic. New diagnostics, new therapies, new biomarkers and systems biology approaches to drug combinations in the Scandinavian summer". Sir David Lane - Opening Lecture in the new Opera House. (Pictured above).

 www.ecco-org.eu

   www.eacr.org




See you at the
16TH ECCO - 36TH ESMO
Multidisciplinary Cancer Congress
STOCKHOLM, 23-27 SEPTEMBER 2011

www.ecco-org.eu

 European Society for Medical Oncology

 EUROPEAN CANCER ORGANISATION

CARCINOGENESIS AWARDS



The awards, sponsored by Oxford University Press, will be presented at the biennial meeting of the European Association for Cancer Research on 26 - 30 June, 2010 in Oslo, Norway.

The Anthony Dipple *Carcinogenesis* Award is for major contributions to research in the field of carcinogenesis, and the *Carcinogenesis* Young Investigator Award is for a recent, significant contribution to carcinogenesis research by an investigator under the age of 40. Nominations, together with reasons for the recommendation and details of relevant publications were sent to the decision-making panel consisting of the editors of *Carcinogenesis* and members of the Editorial Board.

The winner of the Anthony Dipple *Carcinogenesis* Award for 2010 is Dr. David Livingston. Dr. Livingston is at Dana-Farber Cancer Institute at Harvard University. His areas of research include Molecular Pathogenesis of Breast and Ovarian Cancer.

Dr. Thomas Helleday is the 2010 recipient of the *Carcinogenesis* Young Investigator Award. Dr. Helleday is at the Gray Institute for Radiation Oncology & Biology, University of Oxford. He leads the Helleday Laboratories.



Learn more about *Carcinogenesis* online:
WWW.CARCIN.OXFORDJOURNALS.ORG



OXFORD JOURNALS
OXFORD UNIVERSITY PRESS